Adaptive Biotechnologies (ADPT) Short term Debt (2023 - 2026)

Adaptive Biotechnologies has disclosed Short term Debt across 4 years of filings, most recently posting $5.8 million for Q1 2026.

• In Q1 2026, Short term Debt rose 188.61% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 188.61% YoY), while the FY2025 annual figure was $4.6 million, up 436.65% from the prior year.
• Short term Debt came in at $5.8 million for Q1 2026 at Adaptive Biotechnologies, up from $4.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.8 million in Q1 2026 to a low of $865000.0 in Q4 2024.
• Average Short term Debt over 4 years is $3.1 million, with a median of $3.1 million recorded in 2025.
• Year-over-year, Short term Debt jumped 436.65% in 2025 and jumped 188.61% in 2026.
• Over 4 years, Short term Debt stood at $3.2 million in 2023, then slumped by 72.92% to $865000.0 in 2024, then jumped by 436.65% to $4.6 million in 2025, then increased by 25.03% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $5.8 million in Q1 2026, $4.6 million in Q4 2025, and $2.4 million in Q3 2025.